Cannabis O
and O
cocaine O
decrease O
cognitive O
impulse O
control O
and O
functional O
corticostriatal O
connectivity O
in O
drug O
users O
with O
low O
activity O
DBH O
genotypes O
The O
dopamine O
β-hydroxylase O
( O
DβH O
) O
enzyme O
transforms O
dopamine O
into O
noradrenaline O
. O

We O
hypothesized O
that O
individuals O
with O
low O
activity O
DBH O
genotypes O
( O
rs1611115 O
CT/TT O
) O
are O
more O
sensitive O
to O
the O
influence O
of O
cannabis O
and O
cocaine O
on O
cognitive O
impulse O
control O
and O
functional O
connectivity O
in O
the O
limbic O
‘ O
reward O
’ O
circuit O
because O
they O
experience O
a O
drug O
induced O
hyperdopaminergic O
state O
compared O
to O
individuals O
with O
high O
activity O
DBH O
genotypes O
( O
rs1611115 O
CC O
) O
. O

Regular O
drug O
users O
( O
N O
= O
122 O
) O
received O
acute O
doses O
of O
cannabis O
( O
450 O
μg/kg O
THC O
) O
, O
cocaine O
HCl O
300 O
mg O
and O
placebo O
. O

Cognitive O
impulse O
control O
was O
assessed O
by O
means O
of O
the O
Matching O
Familiar O
Figures O
Test O
( O
MFFT O
) O
. O

Resting O
state O
fMRI O
was O
measured O
in O
a O
subset O
of O
participants O
to O
determine O
functional O
connectivity O
between O
the O
nucleus O
accumbens O
( O
NAc O
) O
and O
( O
sub O
) O
cortical O
areas O
. O

The O
influence O
of O
cannabis O
and O
cocaine O
on O
impulsivity O
and O
functional O
connectivity O
significantly O
interacted O
with O
DBH O
genotype O
. O

Both O
drugs O
increased O
cognitive O
impulsivity O
in O
participants O
with O
CT/TT O
genotypes O
but O
not O
in O
CC O
participants O
. O

Both O
drugs O
also O
reduced O
functional O
connectivity O
between O
the O
NAc O
and O
the O
limbic O
lobe O
, O
prefrontal O
cortex O
, O
striatum O
and O
thalamus O
and O
primarily O
in O
individuals O
with O
CT/TT O
genotypes O
. O

Correlational O
analysis O
indicated O
a O
significant O
negative O
association O
between O
cognitive O
impulsivity O
and O
functional O
connectivity O
in O
subcortical O
areas O
of O
the O
brain O
. O

It O
is O
concluded O
that O
interference O
of O
cannabis O
and O
cocaine O
with O
cognitive O
impulse O
control O
and O
functional O
corticostriatal O
connectivity O
depends O
on O
DBH O
genotype O
. O

The O
present O
data O
provide O
a O
neural O
substrate O
and O
behavioral O
mechanism O
by O
which O
drug O
users O
can O
progress O
to O
drug O
seeking O
and O
may O
also O
offer O
a O
rationale O
for O
targeted O
pharmacotherapy O
in O
chronic O
drug O
users O
with O
high O
risk O
DBH O
genotypes O
. O

Methods O
Participants O
Participants O
were O
recruited O
at O
2 O
study O
sites O
( O
i.e O
. O

Maastricht O
and O
Nijmegen O
) O
that O
participated O
in O
this O
multicenter O
trial O
. O

In O
total O
, O
122 O
regular O
users O
of O
cannabis O
and O
cocaine O
( O
male O
N O
= O
96 O
, O
female O
N O
= O
26 O
) O
entered O
the O
study O
. O

On O
average O
, O
participants O
had O
been O
regular O
users O
of O
cannabis O
and O
cocaine O
for O
7 O
yrs O
. O

( O
min-max O
: O
1–23 O
) O
and O
3.2 O
yrs O
. O

( O
min-max:0.5–6 O
) O
respectively O
. O

Participants O
reported O
an O
average O
( O
SD O
; O
min-max O
) O
use O
of O
cannabis O
and O
cocaine O
on O
44.8 O
( O
26.8 O
) O
and O
3.7 O
( O
3.5 O
) O
occasions O
respectively O
during O
the O
previous O
3 O
months O
. O

Participants O
also O
reported O
the O
use O
of O
other O
substances O
such O
as O
MDMA O
( O
88 O
% O
) O
, O
amphetamines O
( O
73 O
% O
) O
, O
mushrooms O
( O
61 O
% O
) O
, O
LSD O
( O
20 O
% O
) O
and O
a O
range O
of O
miscellaneous O
drugs O
( O
60 O
% O
) O
such O
as O
nitrous O
oxide O
, O
MDMA O
crystals O
, O
DMT O
and O
ketamine O
. O

Mean O
( O
SD O
) O
age O
of O
participants O
was O
22.8 O
( O
3.7 O
) O
yrs O
. O

Mean O
( O
SD O
) O
trait O
impulsivity O
score O
as O
assessed O
with O
the O
Barratt O
Impulsiveness O
Scale O
was O
69.5 O
( O
9.6 O
) O
. O

Participants O
were O
recruited O
through O
advertisements O
in O
local O
newspapers O
, O
flyers O
distributed O
at O
targeted O
locations O
( O
e.g. O
, O
college O
campuses O
, O
bars O
, O
night O
clubs O
, O
concerts O
, O
head O
shops O
) O
and O
by O
word O
of O
mouth O
. O

Candidates O
received O
a O
medical O
examination O
by O
the O
medical O
supervisors O
who O
determined O
study O
eligibility O
. O

The O
medical O
supervisor O
checked O
vital O
signs O
, O
conducted O
a O
resting O
12-lead O
electrocardiogram O
( O
ECG O
) O
, O
took O
blood O
and O
urine O
samples O
. O

Participants O
filled O
out O
a O
standard O
questionnaire O
on O
medical O
history O
. O

Standard O
blood O
chemistry O
, O
hematology O
, O
DBH O
genotyping O
and O
drug O
screen O
tests O
were O
conducted O
on O
blood O
and O
urine O
samples O
respectively O
. O

Inclusion O
criteria O
were O
: O
written O
informed O
consent O
; O
age O
18–40 O
yrs O
. O

; O
( O
regular O
) O
use O
of O
cannabis O
( O
i.e O
. O

≥ O
2 O
times/3 O
mo O
) O
; O
cocaine O
use O
at O
least O
5 O
times O
in O
the O
previous O
year O
, O
good O
physical O
and O
mental O
health O
and O
normal O
weight O
( O
BMI O
18-28 O
) O
. O

Exclusion O
criteria O
were O
: O
cocaine O
dependence O
according O
to O
DSM-IV O
criteria O
; O
use O
of O
psychotropic O
medicinal O
drugs O
, O
presence O
or O
history O
of O
psychiatric O
or O
neurological O
disorder O
; O
pregnancy O
or O
lactating O
; O
cardiovascular O
abnormalities O
; O
excessive O
alcohol O
use O
( O
> O
20 O
units/week O
) O
or O
smoking O
( O
> O
15 O
cigarettes/day O
) O
, O
and O
hypertension O
. O

This O
study O
( O
Dutch O
Trial O
Register O
, O
trial O
number O
NTR2127 O
) O
was O
conducted O
according O
to O
the O
code O
of O
ethics O
on O
human O
experimentation O
as O
described O
in O
the O
declaration O
of O
Helsinki O
( O
1964 O
) O
, O
amended O
in O
Seoul O
( O
2008 O
) O
. O

The O
study O
protocol O
was O
approved O
by O
the O
Medical O
Ethics O
Committee O
of O
Maastricht O
University O
. O

Design O
, O
drug O
dose O
and O
administration O
Participants O
entered O
a O
double-blind O
, O
placebo-controlled O
, O
3-way O
crossover O
study O
. O

Treatments O
consisted O
of O
placebo O
, O
450 O
μg/kg O
THC O
( O
cannabis O
plant O
material O
, O
divided O
over O
2 O
successive O
doses O
of O
300 O
and O
150 O
μg/kg O
) O
and O
a O
single O
dose O
of O
300 O
mg O
cocaine O
HCl O
. O

Cannabis O
was O
prepared O
from O
batches O
that O
contained O
11–12 O
% O
THC O
. O

Cannabis O
doses O
were O
tailored O
to O
each O
individual O
subject O
to O
represent O
weight O
calibrated O
doses O
of O
300 O
μg/kg O
THC O
and O
150 O
μg/kg O
THC O
and O
administered O
using O
a O
Volcano O
vaporizer O
( O
Storz O
& O
Bickel O
Volcano O
® O
) O
. O

Cocaine O
HCl O
and O
placebo O
were O
administered O
in O
an O
opaque O
white O
capsule O
. O

Treatments O
were O
administered O
using O
a O
double O
dummy O
technique O
to O
synchronize O
time O
of O
maximal O
drug O
concentrations O
( O
Tmax O
) O
during O
performance O
testing O
and O
resting O
state O
fMRI O
. O

Cocaine O
or O
cocaine O
placebo O
capsules O
were O
administered O
at O
1,25 O
h O
prior O
( O
T0 O
) O
to O
assessment O
of O
performance O
in O
the O
MFFT O
, O
whereas O
the O
first O
dose O
of O
cannabis O
( O
300 O
μg/kg O
THC O
) O
or O
cannabis O
placebo O
was O
inhaled O
15 O
( O
T1 O
) O
min O
prior O
to O
MFFT O
. O

A O
second O
dose O
( O
T2 O
) O
of O
cannabis O
( O
150 O
μg/kg O
THC O
) O
or O
cannabis O
placebo O
was O
administered O
one O
hour O
after O
the O
first O
dose O
( O
T1 O
) O
and O
30 O
min O
prior O
to O
resting O
state O
fMRI O
. O

MFFT O
performance O
was O
collected O
from O
participants O
in O
both O
centers O
. O

However O
only O
participants O
recruited O
by O
the O
Maastricht O
center O
( O
N O
= O
61 O
) O
received O
a O
subsequent O
fMRI O
session O
. O

Treatment O
conditions O
were O
separated O
by O
a O
minimum O
wash-out O
period O
of O
7 O
days O
and O
counterbalanced O
across O
participants O
. O

Vital O
signs O
and O
blood O
samples O
were O
taken O
after O
treatment O
administrations O
( O
T0 O
, O
T1 O
and O
T2 O
) O
. O

Procedures O
Participants O
were O
familiarized O
with O
tests O
and O
procedures O
on O
a O
separate O
training O
day O
prior O
to O
the O
treatment O
conditions O
. O

Participants O
were O
instructed O
to O
refrain O
from O
drug O
use O
( O
except O
for O
cannabis O
) O
throughout O
study O
participation O
. O

In O
the O
morning O
of O
test O
days O
, O
absence O
of O
benzodiazepines O
, O
opiates O
, O
cocaine O
, O
marijuana O
, O
MDMA O
and O
( O
meth O
) O
amphetamine O
was O
assessed O
using O
urine O
screens O
and O
the O
absence O
of O
alcohol O
was O
measured O
using O
a O
breathalyzer O
. O

Female O
participants O
underwent O
an O
additional O
pregnancy O
test O
. O

Participants O
were O
only O
allowed O
to O
proceed O
when O
test O
results O
for O
drug O
( O
except O
cannabis O
) O
and O
alcohol O
use O
and O
pregnancy O
were O
negative O
. O

Participants O
that O
passed O
the O
screen O
test O
received O
a O
standard O
breakfast O
, O
followed O
by O
baseline O
measures O
of O
vital O
signs O
( O
blood O
pressure O
and O
heart O
rate O
) O
and O
a O
sample O
of O
blood O
. O

Matching O
familiar O
figures O
test O
( O
MFFT O
) O
The O
MFFT O
measures O
cognitive O
impulsivity O
. O

It O
involves O
simultaneous O
presentation O
of O
a O
target O
figure O
centered O
on O
the O
left O
half O
of O
the O
screen O
and O
an O
array O
of O
six O
alternatives O
on O
the O
right O
half O
of O
the O
screen O
, O
all O
except O
one O
differing O
in O
one O
or O
more O
details O
from O
the O
target O
figure O
. O

The O
participants O
are O
asked O
to O
find O
the O
item O
that O
exactly O
matches O
the O
target O
item O
by O
pressing O
a O
keyboard O
number O
corresponding O
to O
each O
of O
the O
items O
. O

If O
the O
initial O
selection O
is O
incorrect O
, O
this O
is O
signaled O
with O
a O
beep O
and O
participants O
are O
requested O
to O
respond O
again O
. O

Each O
subject O
is O
given O
2 O
practice O
trials O
followed O
by O
20 O
test O
trials O
. O

Mean O
latency O
of O
the O
first O
response O
and O
total O
number O
of O
errors O
, O
are O
recorded O
and O
used O
to O
calculate O
two O
primary O
measures O
after O
z-transformation O
: O
i.e O
. O

an O
Impulsivity O
score O
( O
I-score O
) O
and O
an O
Efficiency O
score O
( O
E-score O
) O
( O
Messer O
and O
Brodzinsky O
) O
. O

The O
I-score O
is O
a O
composite O
index O
of O
impulsivity O
and O
is O
calculated O
by O
subtracting O
the O
standardized O
score O
of O
the O
mean O
latency O
to O
first O
response O
from O
the O
standardized O
score O
of O
the O
total O
number O
of O
errors O
committed O
( O
Zerror-Zlatency O
) O
. O

The O
E-score O
is O
calculated O
by O
summing O
the O
standardized O
score O
of O
the O
mean O
latency O
to O
first O
response O
from O
the O
standardized O
score O
of O
the O
total O
number O
of O
errors O
committed O
( O
1- O
( O
Zerror O
+ O
Zlatency O
) O
) O
. O

Resting O
state O
fMRI O
MRI O
images O
were O
obtained O
in O
a O
3 O
T O
head-only O
scanner O
( O
Siemens® O
MAGNETOM O
Allegra O
) O
. O

During O
resting O
state O
240 O
EPI O
whole O
brain O
functional O
volumes O
were O
acquired O
( O
TR O
= O
2 O
s O
, O
TE O
= O
30 O
ms O
, O
flip O
angle O
= O
90° O
, O
matrix O
= O
64 O
× O
64 O
× O
32 O
, O
voxel O
size O
= O
3.5 O
× O
3.5 O
× O
3.5 O
mm O
) O
. O

Volunteers O
were O
asked O
to O
relax O
with O
the O
eyes O
open O
during O
resting O
state O
measurement O
. O

For O
anatomical O
reference O
, O
a O
3D O
MPRAGE O
( O
magnetization-prepared O
rapid O
gradient O
echo O
; O
TR O
= O
9.7 O
ms O
, O
TE O
= O
4 O
ms O
, O
flip O
angle O
= O
12° O
, O
matrix O
= O
256 O
× O
256 O
, O
voxel O
size O
= O
1 O
× O
1 O
× O
1 O
mm3 O
) O
image O
data O
set O
was O
acquired O
. O

The O
fMRI O
data O
were O
preprocessed O
using O
SPM8 O
software O
( O
Welcome O
Trust O
Center O
for O
Neuroimaging O
, O
London O
, O
UK O
) O
. O

The O
first O
2 O
volumes O
were O
removed O
from O
each O
fMRI O
data O
set O
to O
allow O
for O
magnetic O
equilibration O
. O

Preprocessing O
included O
3D O
motion O
correction O
and O
slice O
time O
correction O
. O

Individual O
anatomical O
data O
sets O
were O
normalized O
to O
standard O
3-D O
MNI O
space O
. O

Individual O
functional O
images O
were O
realigned O
, O
co-registered O
and O
normalized O
to O
the O
anatomical O
data O
, O
and O
resampled O
to O
a O
voxel O
size O
of O
3 O
× O
3 O
× O
3 O
mm3 O
. O

Spatial O
smoothing O
was O
conducted O
with O
a O
FWHM O
4 O
mm O
Gaussian O
kernel O
. O

Functional O
connectivity O
Functional O
connectivity O
data O
were O
produced O
with O
the O
MATLAB O
toolbox O
DPARSFA O
( O
Chao-Gan O
and O
Yu-Feng O
) O
. O

First O
, O
linear O
trends O
of O
time O
courses O
were O
removed O
followed O
by O
low O
band-pass O
filtering O
( O
0.01–0.08 O
Hz O
) O
of O
the O
preprocessed O
data O
to O
remove O
‘ O
noise O
’ O
attributable O
to O
physiological O
parameters O
. O

In O
addition O
, O
nuisance O
covariates O
including O
6 O
motion O
parameters O
, O
the O
white O
matter O
signal O
and O
the O
CSF O
signal O
were O
removed O
. O

Two O
spheres O
( O
radius O
4 O
mm O
) O
were O
created O
that O
were O
located O
( O
in O
MNI O
space O
) O
in O
the O
NAc O
of O
the O
left O
( O
−9 O
, O
9 O
, O
-9 O
) O
and O
right O
( O
9 O
, O
9 O
, O
-9 O
) O
hemisphere O
( O
Di O
Martino O
et O
al O
. O
) O
. O

Average O
time O
courses O
were O
obtained O
for O
each O
sphere O
separately O
and O
correlational O
analysis O
was O
performed O
voxel O
wise O
to O
generate O
functional O
connectivity O
maps O
for O
each O
sphere O
. O

Finally O
, O
the O
correlation O
coefficient O
map O
was O
converted O
into O
z-maps O
by O
Fisher O
’ O
s O
r-to-z O
transform O
to O
improve O
normality O
. O

Drug-induced O
changes O
in O
functional O
connectivity O
of O
the O
NAc O
have O
been O
shown O
to O
serve O
as O
a O
useful O
marker O
of O
drug O
activity O
in O
in O
the O
brain O
reward O
circuit O
( O
Ramaekers O
et O
al O
. O
) O
. O

Pharmacokinetics O
and O
pharmacogenetics O
Serum O
was O
used O
for O
detection O
of O
cannabinoids O
whereas O
cocaine O
and O
metabolites O
were O
determined O
in O
plasma O
. O

The O
determination O
of O
Δ9-tetrahydrocannabinol O
( O
THC O
) O
, O
11-hydroxy-THC O
( O
THC-OH O
) O
, O
11-nor-9-carboxy-THC O
( O
THC-COOH O
) O
, O
cocaine O
( O
COC O
) O
, O
benzoylecgonine O
( O
BZE O
) O
and O
ecgonine O
methyl O
ester O
( O
EME O
) O
in O
plasma O
was O
performed O
in O
a O
specialized O
forensic-toxicological O
laboratory O
using O
validated O
procedures O
38,39 O
. O

DBH O
genotype O
was O
analyzed O
after O
DNA O
isolation O
from O
blood O
collected O
at O
medical O
screening O
using O
standard O
protocols O
. O

The O
DBH O
polymorphism O
( O
rs1611115 O
) O
was O
genotyped O
using O
restriction O
fragment O
length O
polymorphism O
( O
RFLP O
) O
analysis O
. O

PCR O
was O
performed O
on O
50 O
ng O
genomic O
DNA O
using O
0.2 O
μM O
forward O
primer O
( O
5 O
’ O
-TGAATGTGCCCCTAAGGCTA-3 O
’ O
) O
and O
0.2 O
μM O
reverse O
primer O
( O
5 O
’ O
-CACCTCTCCCTCCTGTCCTCTCGC-3 O
’ O
) O
, O
0.25 O
mM O
dNTPs O
, O
2 O
U O
Taq O
DNA O
polymerase O
( O
Invitrogen O
, O
Breda O
, O
The O
Netherlands O
) O
in O
a O
1× O
PCR O
optimization O
buffer O
A O
( O
30 O
mM O
Tris-HCl O
pH O
8.5 O
, O
7.5 O
mM O
( O
NH4 O
) O
2SO4 O
, O
0.75 O
mM O
MgCl2 O
) O
. O

The O
cycling O
conditions O
were O
5 O
min O
92 O
°C O
, O
followed O
by O
35 O
cycles O
of O
1 O
min O
92 O
°C O
, O
1 O
min O
59 O
°C O
, O
1 O
min O
72 O
°C. O
, O
and O
a O
subsequent O
5 O
min O
72 O
°C.To O
purify O
the O
PCR-products O
, O
NucleoFast96 O
plates O
( O
Macherey-Nagel O
, O
Düren O
, O
Germany O
) O
were O
used O
. O

Restriction O
reaction O
was O
performed O
in O
a O
total O
volume O
of O
15 O
μl O
, O
containing O
10 O
μl O
purified O
PCR-product O
, O
5 O
U O
HhaI O
, O
1× O
NEBuffer O
4 O
and O
1× O
BSA O
. O

Digestion O
was O
performed O
at O
37 O
°C O
for O
16 O
h O
, O
which O
resulted O
in O
two O
fragments O
of O
200 O
bp O
and O
24 O
bp O
for O
the O
C O
allele O
, O
the O
T O
variant O
remained O
uncut O
( O
224 O
bp O
) O
. O

Statistics O
A O
total O
of O
122 O
participants O
entered O
the O
study O
. O

DBH O
genotype O
data O
was O
missing O
in O
6 O
participants O
and O
MFFT O
datasets O
of O
another O
6 O
participants O
were O
incomplete O
, O
due O
to O
technical O
failures O
. O

Consequently O
, O
110 O
participants O
with O
complete O
datasets O
entered O
the O
statistical O
analyses O
of O
MFFT O
data O
. O

For O
analysis O
, O
individuals O
with O
low O
activity O
DBH O
genotypes O
, O
i.e O
. O

CT O
( O
N O
= O
33 O
) O
and O
TT O
( O
N O
= O
4 O
) O
, O
were O
pooled O
( O
CT/TT O
) O
and O
compared O
to O
CC O
homozygotes O
( O
N O
= O
73 O
) O
. O

A O
total O
of O
61 O
participants O
( O
the O
Maastricht O
sample O
) O
participated O
in O
resting O
state O
measures O
. O

fMRI O
datasets O
were O
incomplete O
for O
22 O
participants O
due O
to O
technical O
failures O
or O
due O
to O
excessive O
movement O
during O
drug O
conditions O
, O
rendering O
39 O
participants O
with O
complete O
fMRI O
datasets O
. O

DBH O
genotype O
was O
missing O
in O
4 O
of O
those O
participants O
, O
which O
rendered O
35 O
participants O
with O
complete O
datasets O
to O
test O
for O
Drug O
x O
DBH O
interactions O
on O
functional O
connectivity O
. O

Effects O
on O
impulse O
control O
tasks O
from O
oral O
THC O
and O
cocaine O
HCl O
in O
dosages O
similar O
to O
those O
proposed O
for O
this O
study O
have O
achieved O
statistical O
significance O
in O
within O
subject O
designs O
employing O
20 O
or O
less O
participants O
( O
Fillmore O
et O
al O
. O

; O
Ramaekers O
et O
al O
. O

; O
Ramaekers O
and O
Kuypers O
) O
. O

Assuming O
an O
omnibus O
p O
< O
0.05 O
and O
power O
= O
0.8 O
, O
we O
estimated O
that O
the O
present O
study O
employing O
122 O
subjects O
would O
enable O
detection O
of O
performance O
differences O
between O
drug O
treatments O
with O
an O
effect O
size O
of O
0.3 O
( O
i.e. O
, O
a O
signal O
change O
of O
.3 O
times O
the O
standard O
deviation O
) O
in O
within O
subject O
comparisons O
. O

In O
addition O
, O
we O
estimated O
that O
between O
DBH O
group O
comparisons O
of O
genotypes O
would O
enable O
detection O
of O
performance O
differences O
with O
an O
effect O
size O
of O
.7 O
and O
.4 O
for O
sizes O
of O
N O
= O
30 O
and O
N O
= O
60 O
respectively O
. O

Straightforward O
power O
analysis O
for O
imaging O
data O
is O
less O
feasible O
. O

Because O
fMRI O
data O
analysis O
consists O
of O
a O
very O
large O
number O
of O
non-independent O
multiple O
comparisons O
, O
a O
proper O
power O
analysis O
with O
correction O
for O
multiple O
comparisons O
requires O
computer O
simulation O
. O

In O
addition O
, O
statistical O
power O
is O
not O
the O
same O
( O
i.e. O
, O
homogenous O
) O
over O
the O
brain O
, O
but O
varies O
across O
brain O
regions O
( O
Petersson O
et O
al O
. O
) O
. O

A O
common O
approach O
in O
the O
functional O
neuroimaging O
community O
is O
to O
estimate O
the O
number O
of O
subjects O
from O
previous O
empirical O
experience O
in O
the O
field O
, O
particularly O
when O
pilot O
data O
are O
lacking O
and O
analyses O
include O
the O
whole O
brain O
or O
multiple O
regions O
of O
interest O
( O
Mumford O
) O
. O

Previous O
resting O
state O
fMRI O
studies O
have O
employed O
15–20 O
subjects O
for O
showing O
significant O
drug O
effects O
( O
Honey O
et O
al O
. O

; O
Kelly O
et O
al O
. O

; O
Ramaekers O
et O
al O
. O

; O
Schrantee O
et O
al O
. O
) O
. O

Based O
on O
these O
experiences O
we O
expected O
no O
problem O
to O
demonstrate O
drug O
effects O
on O
fMRI O
measures O
in O
60 O
participants O
and O
that O
sample O
sizes O
of O
subgroups O
DBH O
genotypes O
( O
N O
= O
15–30 O
) O
would O
be O
sufficient O
for O
demonstrating O
between O
group O
differences O
. O

MFFT O
measures O
were O
analyzed O
with O
SPSS O
21.0 O
using O
a O
GLM O
univariate O
analysis O
of O
variance O
( O
ANOVA O
) O
with O
Drug O
( O
3 O
levels O
; O
placebo O
, O
cannabis O
and O
cocaine O
) O
as O
within O
subject O
factor O
and O
DBH O
genotype O
( O
2 O
levels O
; O
CC O
and O
CT/TT O
) O
as O
between O
group O
factor O
. O

The O
model O
tested O
for O
main O
effects O
of O
Drug O
, O
DBH O
genotype O
and O
their O
interaction O
. O

Significant O
main O
effects O
were O
subsequently O
followed O
by O
drug-placebo O
contrasts O
to O
establish O
the O
separate O
effects O
of O
cannabis O
( O
2 O
within O
subject O
levels O
; O
placebo O
and O
cannabis O
) O
and O
cocaine O
( O
2 O
within O
subject O
levels O
; O
placebo O
and O
cocaine O
) O
and O
their O
interaction O
with O
DBH O
genotype O
( O
2 O
between O
group O
levels O
; O
CC O
and O
CT/TT O
) O
. O

Functional O
connectivity O
data O
( O
i.e O
. O

correlation O
coefficient O
maps O
for O
each O
individual O
in O
each O
treatment O
condition O
) O
were O
analysed O
in O
2 O
GLM O
models O
of O
ANOVA O
in O
SPM8 O
. O

In O
the O
first O
GLM O
, O
complete O
datasets O
of O
39 O
participants O
were O
analysed O
using O
ANOVA O
with O
Drug O
( O
3 O
levels O
) O
as O
within O
subject O
factor O
. O

The O
GLM O
model O
established O
the O
effects O
of O
cannabis O
and O
cocaine O
separately O
by O
means O
of O
drug-placebo O
contrasts O
. O

DBH O
genotyping O
was O
only O
available O
for O
35 O
participants O
( O
CC O
genotype O
N O
= O
22 O
; O
CT/TT O
genotype O
N O
= O
13 O
) O
that O
were O
included O
in O
GLM O
1 O
. O

Therefore O
a O
2nd O
GLM O
was O
conducted O
that O
included O
35 O
participants O
for O
which O
both O
resting O
state O
and O
DBH O
data O
sets O
were O
complete O
. O

These O
data O
were O
entered O
in O
an O
ANOVA O
with O
Drug O
( O
3 O
levels O
) O
as O
within O
subject O
factor O
and O
DBH O
genotype O
( O
2 O
levels O
) O
as O
between O
group O
factor O
. O

From O
this O
model O
, O
main O
effects O
of O
DBH O
genotype O
and O
its O
interaction O
with O
cannabis O
and O
cocaine O
treatment O
were O
identified O
. O

The O
statistical O
threshold O
was O
set O
at O
p O
< O
.05 O
FWE O
cluster O
corrected O
( O
cluster O
size O
> O
50 O
) O
. O

Finally O
, O
voxel O
wise O
correlation O
analysis O
between O
FC O
data O
and O
MFFT O
composite O
measures O
of O
Impulsivity O
and O
Efficiency O
were O
conducted O
. O

